Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anxiety; Generalized Clear all
Recruiting Phase 2 Interventional

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

NCT06376734
View directory record Official record
Conditions
Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia, Generalized Anxiety Disorder, Mood Disorders, Psychiatric Disorder, Mental Disorder, Depression, Anxiety
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Sunnyvale, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 10, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Litchfield Park, Arizona • Costa Mesa, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT05749055
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ENX-102, Placebo
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
32
States / cities
Phoenix, Arizona • Garden Grove, California • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 10, 2026, 9:22 AM EDT
Recruiting No phase listed Observational

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

NCT07389473
View directory record Official record
Conditions
ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic Medications
Drug
Lead sponsor
Gaize
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Not listed Not applicable Interventional

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

NCT01687764
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions
Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention
Other · Behavioral
Lead sponsor
Hospital de Clinicas de Porto Alegre
Other
Eligibility
7 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00734071
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Anaheim, California • Arcadia, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 10, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00735267
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Arcadia, California + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Cognitive Control in the Transdiagnostic Conceptualization of "Intrusive Thoughts"

NCT03414619
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Major Depressive Disorder
Interventions
Cognitive Control Tasks and Script Driven Imagery
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390650
View directory record Official record
Conditions
Anxiety
Interventions
Saredutant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

NCT01470469
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
Interventions
SPD503 (extended-release Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Carson, California • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

An Innovative Tailored Intervention for Improving Children's Postoperative Recovery (WebTIPS)

NCT03730259
View directory record Official record
Conditions
Anxiety, Pain, Postoperative Behavior
Interventions
Web-based Tailored Intervention Preparation for Surgery
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Year to 12 Years
Enrollment
1,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Orange, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Problem Solving Intervention for Hospice Caregivers

NCT03712410
View directory record Official record
Conditions
Anxiety Generalized, Quality of Life, Depression
Interventions
PISCES
Behavioral
Lead sponsor
George Demiris, PhD
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

NCT00106860
View directory record Official record
Conditions
Anxiety Disorder
Interventions
a benzodiazepine drug
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
13
States / cities
Bradenton, Florida • Jacksonville, Florida • St. Petersburg, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Adapting an Effective CBT for Comorbidity to a Computer-Delivered Format

NCT03300232
View directory record Official record
Conditions
Generalized Anxiety Disorder, Panic Disorder, Social Anxiety, Alcohol Use Disorder
Interventions
Computer-based VC-CBT
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Attention Training for Generalized Anxiety Disorder

NCT00602563
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
AMP, Applied Relaxation (AR), Clinical Monitoring (CM), Combining the AMP and AR
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 65 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

NCT03829241
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
53
States / cities
Little Rock, Arkansas • Colton, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 10, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

ACT for Individuals With MNCD and Their Care Partners

NCT07239609
View directory record Official record
Conditions
Depression in Adults, Anxiety Disorder Generalized, Grief
Interventions
Acceptance Commitment Therapy
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390533
View directory record Official record
Conditions
Generalized Anxiety
Interventions
Saredutant, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 10, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Stepped Care Treatment for Anxiety Resilience

NCT07228143
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Separation Anxiety Disorder, Specific Phobia, Obsessive Compulsive Disorder (OCD), Panic Disorder (With or Without Agoraphobia)
Interventions
Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A)
Behavioral
Lead sponsor
Andrew Wiese
Other
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

NCT00266409
View directory record Official record
Conditions
Generalized Anxiety Disorder, Panic Disorder
Interventions
Niravam, SSRI/SNRI
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 10, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT06701903
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Computerized Intervention Targeting the Error-Related Negativity and Balance N1 in Anxious Children

NCT05503017
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Obsessive-Compulsive Disorder
Interventions
Psycho-social, computerized intervention targeting error sensitivity, Psycho-social, computerized intervention on healthy lifestyle choices
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
9 Years to 12 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 9:22 AM EDT